This site requires JavaScript to be enabled to work properly. Please modify your settings or use a different browser to continue

       

Leaving GSK Pro

You are leaving GSK Pro to visit a separate website not associated with GSK Pro, a portal for US Healthcare Professionals.There are website links to third-party sites on GSK Pro. GSK is not responsible for content on third-party websites.

Continue

Cancel

Popup

Vaccine Patient Assistance

Coding for GSK Vaccines

Order GSK Vaccines

BOOSTRIX is a vaccine indicated for active booster immunization against tetanus, diphtheria, and pertussis. BOOSTRIX is approved for use as a single dose in individuals aged 10 years and older.

Severe allergic reaction after a previous dose of any tetanus toxoid-, diphtheria toxoid-, or pertussis antigen-containing vaccine, or to any component of BOOSTRIX, or encephalopathy within 7 days of a previous pertussis antigen-containing vaccine is a contraindication.

Safety profile of BOOSTRIX in adolescents 10-18 years of age and adults 19-64 years of age

  • In clinical studies in adolescents 10-18 years of age, 4949 adolescents were vaccinated with a single dose of BOOSTRIX1
  • In clinical studies in adults 19 years of age and older, 4076 adults were vaccinated with a single dose of BOOSTRIX. Of these adults, 1104 were 65 years of age and older1

Solicited local reactions or general adverse events
within 15 days of vaccination1

* P<0.05.
† Mid-upper region of the vaccinated arm.
‡ Gastrointestinal symptoms included nausea, vomiting, diarrhea, and/or abdominal pain.
§ Oral temperatures or axillary temperatures.
ii Oral temperatures.
Td = tetanus and diphtheria.
Tdap = tetanus, diphtheria, and acellular pertussis.

Safety profile of BOOSTRIX in adults 65 years of age and older

  • In a clinical trial in adults 65 years of age and older, 887 patients were vaccinated with a single dose of BOOSTRIX1
  • Overall safety profile in this age group was comparable between BOOSTRIX and Td vaccine1
  • No increase in local and general reactogenicity compared to Td vaccine1

Solicited local reactions or general adverse events within 4 days of vaccination

* Gastrointestinal symptoms included nausea, vomiting, diarrhea, and/or abdominal pain.
† Oral temperatures.

References:

  1. Prescribing Information for BOOSTRIX.
  2. Prescribing Information for Adacel.
  3. Pichichero ME, Blatter MM, Kennedy WA, Hedrick J, Descamps D, Friedland LR. Acellular pertussis vaccine booster combined with diphtheria and tetanus toxoids for adolescents. Pediatrics. 2006;117(4):1084-1093.
  4. Blatter M, Friedland LR, Weston WM, Li P, Howe B. Immunogenicity and safety of a tetanus toxoid, reduced diphtheria toxoid and three-component acellular pertussis vaccine in adults 19-64 years of age. Vaccine. 2009;27(5):765-772.
  5. American Medical Association. 2013 Current Procedural Terminology (CPT) Professional Edition. 4th rev ed. Chicago, IL: American Medical Association; 2012.